Development of LNP/mRNA systems for direct transfection and generation of functional Chimeric Antigen Receptor (CAR) T-cells in-vivo for treatment of blood and other cancer cell types

开发 LNP/mRNA 系统，用于在体内直接转染和生成功能性嵌合抗原受体 (CAR) T 细胞，用于治疗血液和其他癌细胞类型

• 批准号: 463373
• 负责人: Cullis Pieter R
• 金额: $ 62.42万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=463373&lang=en
• 关键词: Cancer; Cart Therapy; Gene Therapy; Immunotherapy; Lipid Nanoparticles; Mrna

Chimeric Antigen Receptor (CAR) T cell therapy is relatively new and exciting form of cancer therapy which uses a patients own re-programmed immune cells to specifically target and destroy cancer cells. In this treatment, T cells (a type of immune cell) a

嵌合抗原受体(CAR)T细胞治疗是一种相对较新和令人兴奋的癌症治疗形式，它使用患者自己重新编程的免疫细胞来特异性地靶向和摧毁癌细胞。在这种治疗中，T细胞(一种免疫细胞)